2022
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
Gandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SAK, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nature Communications 2022, 13: 1547. PMID: 35301314, PMCID: PMC8930970, DOI: 10.1038/s41467-022-29104-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionVirologic responsePersistent SARS-CoV-2 infectionResistance mutationsPre-treatment specimensB-cell deficiencyRemdesivir resistanceRemdesivir therapyViral sheddingCase reportAntiviral agentsPatientsCombinatorial therapyInfectionTherapyWhole-genome sequencingTreatmentImportance of monitoringDe novo emergenceFold increaseRNA-dependent RNA polymeraseNovo emergencePotential benefitsMutationsIndolent
2013
Generating protective immunity against genital herpes
Shin H, Iwasaki A. Generating protective immunity against genital herpes. Trends In Immunology 2013, 34: 487-494. PMID: 24012144, PMCID: PMC3819030, DOI: 10.1016/j.it.2013.08.001.Peer-Reviewed Original ResearchConceptsGenital herpesHerpes simplex virus infectionSimplex virus infectionSignificant risk factorsClinical vaccine trialsRecurrent symptomsHSV infectionProtective immunityViral sheddingVaccine trialsRisk factorsChronic diseasesVirus infectionHIV-1Clear infectionAntiviral drugsHost responseHerpesVaccine designInfectionMillions of peopleSpread of diseaseDiseaseRecent studiesVaccine